FranceThe article discusses the challenges faced by pharmaceutical candidates in clinical trials, noting that only one out of ten drugs successfully progresses to market approval. Scientists are exploring the use of artificial intelligence to expand their data sets by creating virtual patient cohorts and digital twins. This approach aims to improve efficiency and reduce costs in drug development while potentially accelerating the availability of new treatments.
Bias read (Center): The article presents information about the application of AI in clinical research without overtly favoring any particular political ideology or stakeholder group. It focuses on scientific advancements and industry practices rather than advocating for specific policies or criticizing governmental or党
Why factuality (85): The article discusses the use of AI-generated virtual patients and digital twins in clinical trials, citing a statistic that only one out of ten drug candidates successfully progresses to market. While no primary source is available, this claim aligns with general industry knowledge and cross-source
Why objectivity (75): The tone is informative and forward-looking, focusing on the potential benefits of AI in clinical research. It presents the topic objectively but includes some speculative language such as 's'invitent dans les essais cliniques,' which suggests an optimistic view of the technology's role. There is no
